All In MedTech

Device Trial Radar · NCT06106594

VOLT CE Mark Study

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 24, 2023

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Oct 30, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™ X EP System EnSite™ Pulsed Field Ablation Module (for simplicity of reference this device collection will hereafter be referred to as the Volt™ PFA system) for the treatment of symptomatic, recurrent, drug-refractory paroxysmal and persistent atrial fibrillation.

Conditions

  • Atrial Arrhythmia
  • Atrial Fibrillation
  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation

Interventions

  • Pulsed Field AblationDevice

    Pulsed field ablation using the Volt PFA System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7-days of any ablation procedure that uses the Volt PFA System.Time frame: 7-days
  2. Acute procedural effectiveness summarized as the rate of pulmonary veins treated with the Volt PFA system that are isolated at the end of the index ablation procedure.Time frame: During procedure
  3. Long-term 6-month effectiveness summarized as the rate of freedom from documented AF/AFL/AT episodes of >30 seconds duration after the index ablation procedure through 6 months of follow-up.Time frame: 6 months

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • The Prince Hospital

    Chermside, Queensl, Australia

  • Royal Adelaide Hospital

    Adelaide, Saustrl, Australia

  • Monash Health

    Clayton, Victoria, Australia

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.